Dopamine D 1 receptor involvement in latent inhibition and overshadowing

International Journal of Neuropsychopharmacology

Volumn 15, Issue 10, 2012, Pages 1513-1523

  Nelson, Andrew J D ^a   Thur, Karen E ^a   Cassaday, Helen J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

D 1 receptor; latent inhibition; overshadowing; SCH 23390; SKF 81297

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG EFFECT; LATENT INHIBITION; MALE; MENTAL TASK; NONHUMAN; OVERSHADOWING; PRIORITY JOURNAL; RAT; STIMULUS RESPONSE; ANIMAL; CONDITIONING; DRUG ANTAGONISM; INHIBITION (PSYCHOLOGY); PHYSIOLOGY; REACTION TIME; WISTAR RAT;

AMPHETAMINE; ANIMALS; BENZAZEPINES; CONDITIONING (PSYCHOLOGY); DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INHIBITION (PSYCHOLOGY); MALE; RATS; RATS, WISTAR; REACTION TIME; RECEPTORS, DOPAMINE D1;

EID: 84867253520     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001751     Document Type: Article

References (47)

1. Bay-Richter C, O'Tuathaigh CM, O'Sullivan G, Heery DM, et al. (2009). Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action. International Journal of Neuropsychopharmacology 12, 403-414.
2. Bleuler E (1911). Dementia Praecox or the Group of Schizophrenias. New York: International Universities Press. Translated 1950.
3. Briggs CA, Pollock NJ, Frail DE, Paxson CL, et al. (1991). Activation of the 5-HT1C receptor expressed in Xenopus oocytes by the benzazepines SCH 23390 and SKF 38393. British Journal of Pharmacology 104, 1038-1044.
4. Cassaday HJ, Moran PM (2010). Latent inhibition and other salience modulation effects : same neural substrates? In : Lubow RE, Weiner I (Eds), Latent Inhibition : Cognition, Neuroscience, Applications and Schizophrenia. Cambridge, UK: Cambridge University Press.
5. Cheung THC, Bezzine G, Hampson CL, Body S, et al. (2007). Evidence for the sensitivity of operant timing behaviour to stimulation of D1 receptors. Psychopharmacology 195, 213-222.
6. Crider A, Solomon PR, McMahon MA (1982). Disruption of selective attention in the rat following chronic D-amphetamine administration : relationship to schizophrenic attention disorder. Biological Psychiatry 17, 351-361.
7. Enyny YS, Horvitz JC (2003). Opposing roles of D1 and D2 receptors in appetitive conditioning. Journal of Neuroscience 23, 1584-1587.
8. Feldon J, Shofel A, Weiner I (1991). Latent inhibition is unaffected by direct dopamine agonists. Pharmacology Biochemistry and Behavior 38, 309-314.
9. Feldon J, Weiner I (1991). The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biological Psychiatry 29, 635-646.
10. Gal G, Schiller D, Weiner I (2005). Latent inhibition is disrupted by nucleus accumbens shell lesion but is abnormally persistent following entire nucleus accumbens lesion : the neural site controlling the expression and disruption of the stimulus pre-exposure effect. Behavioral Brain Research 162, 246-255.
11. Gosselin G, Oberling P, Di Scala G (1996). Antagonism of amphetamine-induced disruption of latent inhibition by the atypical antipsychotic olanzapine in rats. Behavioural Pharmacology 7, 820-826.
12. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, et al. (1991). The neuropsychology of schizophrenia. Behavioral and Brain Sciences 14, 1-20.
13. Gray JA, Kumari V, Lawrence N, Young AMJ (1999). Functions of the dopaminergic innervation of the nucleus accumbens. Psychobiology 27, 225-235.
14. Gray JA, Moran PM, Grigoryan G, Peters S, et al. (1997). Latent inhibition : the nucleus accumbens connection revisited. Behavioral Brain Research 88, 27-35.
15. Joseph MH, Peters SL, Gray JA (1993). Nicotine blocks latent inhibition in rats : evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure. Psychopharmacology 110, 187-192.
16. Joseph MH, Peters SL, Moran PM, Grigoryan GA, et al. (2000). Modulation of latent inhibition in the rat by altered dopamine transmission in the nucleus accumbens at the time of conditioning. Neuroscience 101, 921-930.
17. Kapur S (2003). Psychosis as a state of aberrant salience : a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry 160, 3-23.
18. Kapur S (2004). How antipsychotics become anti-'psychotic '-from dopamine to salience to psychosis. Trends in Pharmacological Sciences 25, 402-406.
19. Loskutova LV, Kostyunina NV, Dubrovina NI (2010). Involvement of different types of dopamine receptors in the formation of latent inhibition of a conditioned passive avoidance reaction in rats. Neuroscience and Behavioral Physiology 40, 483-487.
20. Loskutova LV, Luk'yanenko FYA, Il'yuchenok RYU (1990). Modeling of latent inhibition in rats by activation of the central serotoninergic system. Neuroscience and Behavioral Physiology 20, 541-542.
21. Lubow RE, Moore AU (1959). Latent inhibition: the effect of non-reinforced preexposure to the conditional stimulus. Journal of Comparative and Physiological Psychology 52, 415-419.
22. Millan MJ, Newman-Tancredi A, Quentric Y, Cussac D (2001). The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors. Psychopharmacology 156, 58-62.
23. Moran PM, Fischer JM, Hitchcock JM, Moser PC (1996). Effects of clozapine on latent inhibition in the rat. Behavioural Pharmacology 7, 42-48.
24. Nelson AJD, Thur KE, Marsden CA, Cassaday HJ (2010). Catecholaminergic depletion within the prelimbic medial prefrontal cortex enhances latent inhibition. Neuroscience 170, 99-106.
25. Nelson AJD, Thur KE, Marsden CA, Cassaday HJ (2011a). Dopamine in nucleus accumbens: salience modulation in latent inhibition and overshadowing. Journal of Psychopharmacology. Published online : 24 January 2011. doi :10.1177/0269881110389211.
26. Nelson AJD, Thur KE, Horsley RR, Spicer C, et al. (2011b). Reduced dopamine function within the medial shell of the nucleus accumbens enhances latent inhibition. Pharmacology Biochemistry and Behavior 98, 1-7.
27. O'Callaghan M, Bay-Richter C, Mathur N, Fone KCF, et al. (2010). Latent inhibition in D1 dopamine receptor knock out mice. Journal of Psychopharmacology 24 (Suppl.), A41.
28. O'Tuathaigh CMP, Moran PM (2002). Evidence for dopamine D1 receptor involvement in the stimulus selection task overshadowing in the rat. Psychopharmacology 162, 225-231.
29. O'Tuathaigh CMP, Moran PM (2004). The effect of sulpiride on amphetamine induced disruption of overshadowing in the rat. Progress in Neuro- psychopharmacology and Biological Psychiatry 28, 1249-1253.
30. O'Tuathaigh CMP, Salum C, Young AMJ, Pickering AD, et al. (2003). The effect of amphetamine disruption on Kamin blocking and overshadowing. Behavioural Pharmacology 14, 315-322.
31. Pavlov IP (1927). Conditioned Reflexes (G. V. Anrep, Trans.). Oxford, UK: Oxford University Press.
32. Ranaldi R, Beninger RJ (1993). Dopamine D1 and D2 antagonists attenuate amphetamine-produced enhancement of responding for conditioned reward in rats. Psychopharmacology 113, 110-118.
33. Shadach E, Gaisler I, Schiller D, Weiner I (2000). The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin. Neuropsychopharmacology 23, 151-161.
34. Solomon PR, Crider A, Winkelman JW, Turi A, et al. (1981). Disrupted latent inhibition in the rat with chronic amphetamine or haloperidolinduced supersensitivity: relationship to schizophrenic attention disorder. Biological Psychiatry 16, 519-537.
35. St Onge JR, Floresco SB (2009). Dopaminergic modulation of risk-based decision making. Neuropsychopharmacology 34, 681-697.
36. Trimble KM, Bell R, King DJ (2002). Effects of the selective dopamine D(1) antagonists NNC 01-0112 and SCH 39166 on latent inhibition in the rat. Physiology and Behavior 77, 115-123.
37. Vezina P (1996). D1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. Journal of Neuroscience 16, 2411-2420.
38. Vezina P, Stewart J (1989). The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine. Brain Research 499, 108-120.
39. Warburton EC, Joseph MH, Feldon J, Weiner I, et al. (1994). Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron-implications for a possible antipsychotic action of ondansetron. Psychopharmacology 114, 657-664.
40. Weiner I (1990). Neural substrates of latent inhibition : the switching model. Psychological Bulletin 108, 442-461.
41. Weiner I (2003). The 'two-headed' latent inhibition model of schizophrenia : modelling positive and negative symptoms and their treatment. Psychopharmacology 169, 257-297.
42. Weiner I, Arad M (2009). Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behavioural Brain Research 204, 369-386.
43. Weiner I, Feldon J (1987). Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology 91, 248-253.
44. Weiner I, Lubow RE, Feldon J (1984). Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology 83, 194-199.
45. Weiner I, Shadach E, Tarrasch R, Kidron R, et al. (1996). The latent inhibition model of schizophrenia : further validation using the atypical neuroleptic, clozapine. Biological Psychiatry 40, 834-843.
46. Young AM, Moran PM, Joseph MH (2005). The role of dopamine in conditioning and latent inhibition : what, when, where and how? Neuroscience and Biobehavioral Reviews 29, 963-976.
47. Zelikowsky M, Fanselow MS (2010). Opioid regulation of Pavlovian overshadowing in fear conditioning. Behavioral Neuroscience 124, 510-519.